Cohort | Number | Mortality (%) | APIV PM (%) | OE MR |
---|
APIV PM <10% |
FS1 | 5054 | 1.1 | 3.3 | 0.33 |
FS2 | 434 | 5.1 | 5.6 | 0.91 |
FS3 | 41 | 4.9 | 4.9 | 1.00 |
APIV PM <10–25% |
FS1 | 1279 | 7.9 | 16.1 | 0.49 |
FS2 | 490 | 16.1 | 16.8 | 0.96 |
FS3 | 49 | 20.4 | 17.0 | 1.20 |
APIV PM <25–50% |
FS1 | 671 | 21.3 | 35.1 | 0.61 |
FS2 | 411 | 32.1 | 36.3 | 0.89 |
FS3 | 62 | 29.0 | 37.2 | 0.78 |
APIV PM ≥50% |
FS1 | 710 | 65.2 | 75.4 | 0.86 |
FS2 | 393 | 71.5 | 75.8 | 0.94 |
FS3 | 44 | 63.6 | 70.1 | 0.91 |
-
APIV PM Acute Physiology and Chronic Health Evaluation IV (APACHE IV) predicted mortality (%), OE MR observed-expected mortality ratio. Statistical testing for differences between FS for OE MR:APIV PM <10%; FS1 vs FS2 p < 0.0001; FS1 vs FS3 p < 0.0001. APIV PM <10–25%; FS1 vs FS2 p < 0.0001; FS1 vs FS3 p < 0.0001. APIV PM <25–50%; FS1 vs FS2 p < 0.0001; FS1 vs FS3 p = 0.0082. APIV PM ≥50%; FS1 vs FS2 p = 0.0001; FS1 vs FS3 p = 0.3494